(Nicole pictured with her Uncle Richie, whom she runs in honor of for TNT)
The mission of The Leukemia & Lymphoma Society (LLS) is: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.
LLS is the world’s largest voluntary health agency dedicated to blood cancer. LLS funds lifesaving blood cancer research around the world and provides free information and support services.
Our Key Priorities will ensure that: The Leukemia & Lymphoma Society helps blood cancer patients live better, longer lives.
Team in Training (TNT) is a 3-5 month program in which participants achieve/exceed a fundraising commitment in support of the LLS’s Mission while training for an endurance event of their choice (within Team In Training’s offerings). Training program includes coaching, training plan, clinics, and group training sessions. We also offer guaranteed race entry, Pre-race inspiration dinner and travel to the participant’s selected event including airfare and hotel (where applicable). TNT is the opportunity to make your athletic goals a reality while giving back to the cancer community.
September is actually Blood Cancer Awareness Month:
1. Every three minutes, someone in the U.S. is diagnosed and there are few (if any) means of preventing or screening early.
2. In 1964, a child’s chance of surviving acute lymphoblastic leukemia (ALL), the most common form of childhood leukemia, was 3%. Today about 90% of children survive.
3. Since the early 1960s, the survival rates for many blood cancer patients have doubled, tripled or even quadrupled thanks to research and access to better treatments.
4. Nearly 40 percent of new cancer therapies approved by the FDA between 2000 and 2013 were first approved for blood cancer patients.
5. Multi-drug chemotherapy and stem cell transplantation was first successfully developed for blood cancer patients.
Last year alone, LLS invested nearly $80 million in cutting-edge research – bringing the total to more than $1 billion spent to advance cancer therapies and save lives. Yet, despite this progress, more than one third of blood cancer patients still do not survive five years after their diagnosis.
Currently, LLS-funded research teams at multiple institutions are testing different approaches to activate the immune system to kill cancer cells. They helped advance an antibody therapy that helps boost the immune system to attack cancer cells in patients with lymphoma and chronic lymphocytic leukemia (CLL), and are working to advance new FDA-approved targeted therapies to treat patients with CLL and other B-cell cancers. Our goal is to raise $300,000 in 30 days to celebrate.